How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,222 results for

adhd exercise

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5121. Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

with Hyperactivity Aggression Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Behavioral Symptoms Methylphenidate Quetiapine Fumarate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Antidepressive Agents Psychotropic Drugs Antipsychotic Agents Tranquilizing Agents (...) of this questionnaire will be used as secondary efficacy measures of parent-reported aggressive behavior. These scores range from 0-24. Attention Deficit/Hyperactivity Disorder Rating Scale -IV- Parent Version (ADHDRS-IV-Parent Version) [ Time Frame: See Arm/Group - repeated measures ] The Attention Deficit/Hyperactivity Disorder Rating Scale -IV- Parent Version (ADHDRS-IV-Parent:Inv) (Faries, Yalcin, Harder, & Heiligenstein, 2001) is an interviewer-administered semi structured interview with the parent, focusing

2007 Clinical Trials

5122. Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems Study Start Date : September 2008 Actual Primary Completion Date : September 2009 Actual Study Completion Date : October 2009 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment 1 Drug: SPN-810 capsule taken three times a day Experimental: Treatment 2 Drug: SPN-810 capsule taken TID Experimental (...) . Diagnostic and Statistical Manual of Mental Disorders - IV -Text Revision (DSM-IV-TR) diagnosis of ADHD. NCBRF-TIQ disruptive behavior disorder subscale 27 or greater at baseline; AND a score of 2 or more on at least 1 of the following 3 items of the conduct problem subscale: knowingly destroys property, gets in physical fights, physically attacks people. IQ greater than 71. Exclusion Criteria: Current or lifetime diagnosis of bipolar disorder, post-traumatic stress disorder, personality disorder

2008 Clinical Trials

5123. Effectiveness of an Extended Release Stimulant Medication in Treating Preschool Children With ADHD

: Other Study ID Numbers: DDTR BK-TKFND First Posted: July 10, 2008 Last Update Posted: August 23, 2013 Last Verified: August 2013 Keywords provided by john fanton, Baystate Medical Center: Preschool Children ADHD Medication Controlled Study Placebo Mixed Amphetamine Salts Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Amphetamine Central Nervous (...) Sponsor: Baystate Medical Center Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): john fanton, Baystate Medical Center Study Details Study Description Go to Brief Summary: This study will evaluate the safety and effectiveness of extended release mixed amphetamine salts in treating preschool children with attention deficit hyperactivity disorder. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug

2008 Clinical Trials

5124. Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Methylphenidate Transdermal System (MTS) Other: placebo patch Phase 3 Detailed Description: ADHD affects from 3 to 5% of children, persists into adolescence in 40 (...) Numbers: 20405 SPD485.420-Reimherr ( Other Grant/Funding Number: Shire Pharma ) First Posted: July 25, 2007 Results First Posted: January 16, 2015 Last Update Posted: January 16, 2015 Last Verified: January 2015 Keywords provided by frederick reimherr, University of Utah: Attention Deficit Hyperactivity Disorder ADHD Adult Methylphenidate Transdermal System Daytrana Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit

2007 Clinical Trials

5125. Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial

: Assistance Publique - Hôpitaux de Paris Information provided by: Assistance Publique - Hôpitaux de Paris Study Details Study Description Go to Brief Summary: This prospective pilot trial will evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) and pharmacodynamic (PD) properties of mazindol. Condition or disease Attention Deficit Hyperactivity Disorder Detailed Description: The most common intervention for Attention Deficit Hyperactivity Disorder (ADHD) is pharmacological treatment (...) by Assistance Publique - Hôpitaux de Paris: Attention Deficit Hyperactivity Disorder Mazindol Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Mazindol Central Nervous System Stimulants Physiological Effects of Drugs Adrenergic Uptake Inhibitors Neurotransmitter

2007 Clinical Trials

5126. Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

the long-term, safety of Methylphenidate Transdermal System (MTS) in the symptomatic treatment of adolescents aged 13-17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria. The evaluation of safety will be based on treatment-emergent adverse events (TEAEs), laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs), and skin tolerability to MTS based (...) Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents

2007 Clinical Trials

5127. Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

. In addition, they often have unusual responses to sensory experiences, such as certain sounds or the way objects look. Some symptoms of attention deficit hyperactivity disorder (ADHD), such as inattention, hyperactivity, and impulsivity, are also associated with autism. Atomoxetine is a selective norepinephrine reuptake inhibitor that is used to treat ADHD. It works differently, however, than stimulant drugs and may help to reduce ADHD symptoms in children with autism. This study will evaluate (...) ) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD-RS-IV is investigator-administered biweekly during the 8-week double-blind, placebo-controlled phase of the study. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from

2007 Clinical Trials

5128. Atomoxetine Pilot Study in Preschool Children With ADHD

Summary: The purpose of this study is to determine if atomoxetine (a common brand name is Strattera), a medicine that is used for treating older children with Attention Deficit and Hyperactivity Disorder (ADHD), is also safe and helpful for ADHD problems in young children. While atomoxetine is not approved by the FDA for use in children younger than 6 years, the FDA has given permission to study this drug in this age group. Condition or disease Intervention/treatment Phase Attention Deficit (...) with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs

2007 Clinical Trials

5129. Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

by: Armenteros, Jorge L., M.D., P.A. Study Details Study Description Go to Brief Summary: Primary objectives: To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD. To assess the short-term safety and tolerability of risperidone augmentation in the same group of subjects. Condition or disease Intervention/treatment Phase Aggression Drug: Risperidone Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (...) (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Boys and girls ages 7 to 12 years, inclusive Medical/neurological clearance Meets DSM-IV diagnosis of ADHD Treatment with a stimulant medication during the last three weeks Failure to respond to stimulant medication as documented by: Three acts of aggression in the past week, two of which must be acts of physical aggression against other people, objects, or self Aggression Questionnaire (AQ) Predatory

2006 Clinical Trials

5130. Atomoxetine Treatment for ADHD and Marijuana Dependence

: August 4, 2006 Results First Posted: April 9, 2012 Last Update Posted: December 30, 2014 Last Verified: December 2014 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Marijuana Abuse Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Substance-Related Disorders Chemically-Induced Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport (...) ) Information provided by (Responsible Party): Aimee McRae-Clark, Medical University of South Carolina Study Details Study Description Go to Brief Summary: The aim of the study is to determine if atomoxetine treatment combined with motivational enhancement therapy is effective in reducing marijuana use in adult individuals with attention-deficit hyperactivity disorder and marijuana dependence. Condition or disease Intervention/treatment Phase Marijuana Abuse Attention Deficit Disorder With Hyperactivity

2006 Clinical Trials

5131. Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

, 2012 Sponsor: Cephalon Information provided by: Teva Pharmaceutical Industries Study Details Study Description Go to Brief Summary: The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder ADHD Drug: Modafinil Phase 2 Detailed Description: The primary objective of the study (...) relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Modafinil Central Nervous System Stimulants Physiological Effects of Drugs Wakefulness-Promoting Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological Action

2006 Clinical Trials

5132. Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany

Party: Chief Medical Officer, Eli Lilly ClinicalTrials.gov Identifier: Other Study ID Numbers: 11149 B4Z-SB-LYDW ( Other Identifier: Eli Lilly and Company ) First Posted: December 4, 2006 Results First Posted: February 12, 2010 Last Update Posted: February 26, 2010 Last Verified: February 2010 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Pathologic Processes (...) : February 12, 2010 Last Update Posted : February 26, 2010 Sponsor: Eli Lilly and Company Information provided by: Eli Lilly and Company Study Details Study Description Go to Brief Summary: A three-arm, randomized, double-blind, placebo-controlled, Phase 4, multicenter study to compare the efficacy and safety of atomoxetine versus placebo in children and adolescents aged 6 through 17 years with attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD) who

2006 Clinical Trials

5133. Neuropsychological Functioning Among Children With Tourret's Disorder and ADHD

( Other Identifier: National Taiwan University Hospital ) First Posted: December 27, 2006 Last Update Posted: November 14, 2012 Last Verified: September 2008 Keywords provided by National Taiwan University Hospital: Tourette disorder, ADHD, comorbidity, neuropsychological Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Tourette Syndrome Pathologic Processes Attention Deficit and Disruptive Behavior Disorders (...) by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: Tourette's disorder (TD) is a childhood-onset neuropsychiatric disorder, manifesting motor and vocal tics with increased likelihood of comorbid with attention-deficit/hyperactivity disorder (ADHD) and other psychiatric disorders. Literature documents the comorbid condition with ADHD predicts an increased functional deficit among individuals with ADHD. The information about neuropsychological

2006 Clinical Trials

5134. Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

with hyperactivity ADD FAS FASD ADHD Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Attention Deficit Disorder with Hyperactivity Hyperkinesis Fetal Alcohol Spectrum Disorders Disease Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Fetal Diseases Pregnancy Complications Alcohol-Induced Disorders Alcohol-Related Disorders Substance-Related (...) Results First Posted : July 2, 2017 Last Update Posted : July 2, 2017 Sponsor: University of Oklahoma Collaborator: Mark L. Wolraich Information provided by (Responsible Party): Laura J McGuinn, MD, University of Oklahoma Study Details Study Description Go to Brief Summary: Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome. Condition or disease Intervention/treatment Phase Fetal Alcohol Syndrome Attention Deficit Hyperactivity Disorder (ADHD) Drug: Atomoxetine

2007 Clinical Trials

5135. Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD

: University of Oklahoma Collaborators: Mark L. Wolraich, M.D. Eli Lilly and Company Information provided by (Responsible Party): University of Oklahoma Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth. Condition or disease Intervention/treatment Phase Fetal Alcohol Syndrome Attention Deficit Disorder With Hyperactivity (ADHD (...) ) Attention Deficit Disorder (ADD) Drug: Strattera Drug: Placebo Phase 1 Detailed Description: Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol

2007 Clinical Trials

5136. Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

: Attention deficit hyperactivity disorder ADHD clonidine methylphenidate MPH Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Clonidine Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter (...) deficit hyperactivity disorder (ADHD) is a disease characterized by one or more symptoms of hyperactivity, impulsivity, or inattention that interfere with school, home, work, or social settings. ADHD does not have clear physical signs that can be seen in an x-ray or a lab test. The disorder only can be identified by looking for certain behaviors, which vary from person to person. This trial will compare the benefits and side effects of two medications——clonidine and methylphenidate (MPH)——used alone

2006 Clinical Trials

5137. Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

Last Verified: July 2012 Keywords provided by Teva Pharmaceutical Industries ( Cephalon ): ADHD Attention Deficit/Hyperactivity Disorder Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Modafinil Central Nervous System Stimulants Physiological Effects (...) by (Responsible Party): Teva Pharmaceutical Industries ( Cephalon ) Study Details Study Description Go to Brief Summary: Primary objective of this study is to evaluate the safety of treatment with modafinil film-coated tablet. Condition or disease Intervention/treatment Phase Attention Deficit/Hyperactivity Disorder ADHD Drug: Modafinil Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Non-Randomized Intervention Model: Single Group

2005 Clinical Trials

5138. Long Duration Stimulant Treatment Study of Preschoolers With ADHD-Feasibility Study

(ADHD) Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms (...) Information provided by: New York State Psychiatric Institute Study Details Study Description Go to Brief Summary: This study will evaluate if Ritalin LA™ is safe and effective for ADHD treatment in 4-to-5-year olds. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Ritalin LA™ Phase 4 Detailed Description: This is a single site, open-label, four-week feasibility study of long-duration beaded methylphenidate (B-MPH), also known as Ritalin LA™. B-MPH

2005 Clinical Trials

5139. Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

Information provided by: Teva Pharmaceutical Industries Study Details Study Description Go to Brief Summary: An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period) Condition or disease Intervention/treatment Phase ADHD Drug: Modafinil Phase 3 Study Design Go to Layout table for study information Study Type (...) First Posted: September 29, 2005 Last Update Posted: May 9, 2014 Last Verified: May 2014 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Modafinil Central Nervous System Stimulants Physiological Effects of Drugs Wakefulness-Promoting Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological

2005 Clinical Trials

5140. Safety of SPD465 in Treating Adults With ADHD.

and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 1040 participants Allocation: Non-Randomized (...) : September 9, 2005 Last Update Posted: January 16, 2017 Last Verified: January 2017 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Amphetamine Dextroamphetamine Adderall Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>